XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > $XRX files for NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by Richmondon Aug 14, 2021 11:34am

141 Views

Post# 33706096

RE:RE:RE:RE:$XRX files for NASDAQ

XORTEX IS NOT HITTING .60c but CONSOLIDATING at 45:1. Very DIRTY trick being played. Consolidation has never worked ever. The Share price from 45 to 1 at .40c = $18 roughly will end back at a couple of dollars very fast. Mark my words.!!!!! NO TO CONSOLIDATION!!!!! 5:1 @ .40c == $2.00 whuch can tumble back to .40c would be no big deal but 45:1 is BRUTAL...130M o/s at 45:1 = 3M shares. Who goes to NASDAQ with 3M shares. Shareholders being fooled for more PP and more DILUTION...then ROLLBACK.. LOL...Get some show on the road, Xortex....LOL...